X

Trial Profile

Phase II study of TAS-114 in combination with S-1 in patients with advanced gastric cancer refractory to prior chemotherpy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TAS 114 (Primary) ; Gimeracil/oteracil/tegafur
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms TAS114_GC study

Most Recent Events

07 Jan 2019 According to UMIN, the anticipated date for data entry closure is 31 Jan 2019, and the date for conclusion of data analysis is 1 May 2020.
07 Jan 2019 Status changed from suspended to completed.
19 Sep 2018 Status changed from recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com